Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

Clinical trial NCT02576301 · UNKNOWN

Trial details

NCT number: NCT02576301
Sponsor: Mateon Therapeutics
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myelogenous Leukemia Myelodysplastic Syndromes

Start date: 2015-10-01
Primary completion: 2019-10-01
Enrollment: 105

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.